TIANJUDIHE (02479) Announces 2026 Interim Results: Loss Attributable to Shareholders of RMB 2.714 Million, Turning from Profit to Loss Year-on-Year
TIANJUDIHE (02479) Announces 2026 Interim Results: Revenue of RMB 180 Million, Down 26.99% Year-on-Year; Loss Attributable to Shareholders of RMB 2.714 Million, Turning from Profit to Loss Year-on-Year; Loss per Share of RMB 0.05
Text:
TIANJUDIHE (02479) announced its interim results for the six months ended June 30, 2026. The Group recorded revenue of RMB 180 million (unit: same below), a year-on-year decrease of 26.99%; loss attributable to owners of the Company of RMB 2.714 million, turning from profit to loss year-on-year; loss per share of RMB 0.05.
TIANJUDIHE (02479) announced its interim results for the six months ended June 30, 2026. The Group recorded revenue of RMB 180 million (same unit below), a year-on-year decrease of 26.99%; loss attributable to owners of the Company of RMB 2.714 million, turning from profit to loss year-on-year; loss per share of RMB 0.05.
The announcement stated that the decrease in revenue was mainly due to reduced revenue from API market inquiries.
During the reporting period, the suspension of trading in the Company's shares had a material adverse impact on the Group's business development, among which certain major customers of the Group significantly reduced business orders placed with the Group due to concerns over the trading suspension.
Related Articles

Accounting for 11.21% of DUIBA's (01753) total share capital! The largest founder donation to an ESOP by share ratio in Hong Kong stock market history

BANK OF GUIZHOU (06199): Wen Zhichao's qualification to serve as an independent non-executive director has been approved.

TYK MEDICINES-B (02410) Subscription Agreement for Issuance of H Shares Under General Mandate Lapses
Accounting for 11.21% of DUIBA's (01753) total share capital! The largest founder donation to an ESOP by share ratio in Hong Kong stock market history

BANK OF GUIZHOU (06199): Wen Zhichao's qualification to serve as an independent non-executive director has been approved.

TYK MEDICINES-B (02410) Subscription Agreement for Issuance of H Shares Under General Mandate Lapses

RECOMMEND





